Abstract:Background: Invasive fungal infection (IFI) is common in neutropenic patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MD S). Posaconazole is a broad-spectrum triazole antifungal drug with efficacy in prevention of IFI; however, it has not been previously studied as prophylaxis in a Chinese population. Methods: This multicenter, randomized study in China enrolled AML and MDS patients with persistent chemotherapy-induced neutropenia. Prophylaxis with posaconazole or fiuconazole was administered for a maximum of 12 weeks, or until patients recovered from neutropenia and achieved complete remission or an IFI occurred. The primary endpoint was incidence of proven, probable, or possible IFI during treatment. Clinical failure rate, all-cause mortality and time to first systemic antifungal treatment were secondary endpoints. Results: Patients were randomized to receive posaconazole (n = 129) or fluconazole (n= 123); 117 patients in each group were included in the statistical analysis. The incidence of proven, probable or possible IFI was 9.4% (11/117) and 22.2% (26/117) in the posaconazole and fluconazole groups, respectively (p = 0.0114). The clinical failure rate was numerically lower in the posaconazole group (37/117 (31.6%; 95%CI: 23.3 - 40.9)) than in the fiuconazole group (49/117 (41.88%; 95% CI: 32.8 - 51.4)) (p = 0.168). Patients receiving posaconazole had a later onset of first systematic antifungal treatment than those receiving fluconazole (p = 0.0139). The most common important adverse events were liver function abnormalities (11 patients (8.8%) on posaconazole and 6 (5.0%) on fluconazole (p = 0.221)). Conclusions: Posaconazole demonstrates efficacy as prophylaxis against IFI in high-risk neutropenic Chinese patients and is well tolerated during long-term use (ClinicalTrials.gov number, NCT00811928).

Successful treatment for chromoblastomycosis caused by Fonsecaea monophora: a report of three cases in Guangdong, China.

Successful treatment for chromoblastomycosis caused by <i>Fonsecaea monophora</i>: a report of three cases in Guangdong, China

A Refractory Case of Chromoblastomycosis Due to Fonsecaea Monophora with Improvement by Photodynamic Therapy.

Chromoblastomycosis caused by Fonsecaea monophora in North China:first case report and laboratory study

Successful Treatment of Chromoblastomycosis of 10-Year Duration Due to Fonsecaea Nubica

Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: an Update from the CHIF-NET Study

Chromoblastomycosis caused by a meristematic mutant of Fonsecaea monophora.

Successful treatment of Candida tropicalis osteomyelitis with Micafungin in a leukemia patient

Successfully treatment of chromoblastomycosis with itraconazole and terbinafine association:a case report

Synergistic effect of terbinafine and amphotericin B in killing Fonsecaea nubica in vitro and in vivo

Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study

Successful Voriconazole Treatment of Talaromyces Marneffei Infection in an HIV-negative Patient with Osteolytic Lesions.

In Vitro Interaction of Terbinafine with Itraconazole and Amphotericin B Against Fungi Causing Chromoblastomycosis in China.

Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora.

Resazurin to determine the minimum inhibitory concentration on antifungal susceptibility assays for Fonsecaea sp. using a modified EUCAST protocol

A Chronic Chromoblastomycosis Model by Fonsecaea Monophora in Wistar Rat

Case Report: Successful Treatment of Cerebral Phaeohyphomycosis with Voriconazole: A Case Report and Literature Review

New possibilities for chromoblastomycosis and phaeohyphomycosis treatment: identification of two compounds from the MMV Pathogen Box® that present synergism with itraconazole

Chromoblastomycosis: still a therapeutic challenge

Posaconazole Vs. Fluconazole As Invasive Fungal Infection Prophylaxis in China: A Multicenter, Randomized, Open-Label Study

In vitro susceptibility of chromoblastomycosis agents to five antifungal drugs and to the combination of terbinafine and amphotericin B